Ranibizumab is a monoclonal antibody fragment (FAB), as well as an antibody against vascular endothelial growth factor (VEGF) and an inhibitor of angiogenesis. It is obtained from the same parent mouse antibody as bevacizumab, but is much smaller than the parent molecule and can bind more tightly to vascular endothelial growth factor-A (VEGF-A). ‌

Market Development Status

Market size: According to our research data, the global revenue of the ranibizumab market is expected to reach $3799 million in 2024, an increase of 3.14% compared to 2023. In the future, with the increasing number of people suffering from ophthalmic diseases, the demand for ranibizumab in the market will increase, which will drive further market growth. It is expected that by 2029, the global market revenue of ranibizumab will increase to $4208 million. The estimated CAGR for 2024-2029 is 2.07%.

Market competition: Roche and Novartis are the core global suppliers of ranibizumab, holding approximately 98% of the market share. ‌

Analysis of Downstream Application Pattern

Leizumab is mainly used to treat eye neovascular diseases, including wAMD、DR、DEM、Mcnv、RVO. Among them, the treatment of wAMD is the largest downstream application market, with an estimated application share of 43.37% in 2024.

Source: www.globalmarketmonitor.com

Analysis of Market Development in Major Regions

From a regional perspective, the global market for ranibizumab is concentrated in three major regions: North America, Europe, and Asia Pacific. Among them, North America is the largest sales market. Data shows that the sales of ranibizumab in North America are expected to reach 1335.2k vails in 2024, accounting for an estimated 45.35% of the global total consumption; The European and Asia Pacific markets are expected to rank second and third with a share of 28.50% and 17.44%, respectively.

Regions	Sales Volume (K Vails)	Proportion
North America	1335.2	45.35%
Europe	839.0	28.50%
Asia Pacific	513.5	17.44%
South America	121.2	4.12%
Middle East & Africa	135.3	4.60%